Patent US5202424A successfully refreshed from Google Patents.
US5202424A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
Assignee: BBDX Inc
•
Filing: 1991-08-23
•
Granted: 1993-04-13
•
Expires: 2011-08-23
Abstract
Abstract The present invention relates to a method and associated agents for measuring the presence and amount of advanced glycosylation endproducts in cells and fluids. The methods take advantage of the existence of receptors and receptor complexes for AGEs and include receptor-containing ligands comprising whole mesangial and other cells, mesangial cellular fragments and protein extracts therefrom. Competitive assays, sandwich assays and assays involving AGE antisera are disclosed. Numerous diagnostic applications are defined and test kits are also contemplated.
Inventors
- 👤 Helen Vlassara
- 👤 Anthony Cerami
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 14:15
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/64; A61K31/00; A61K31/13; A61K31/155; A61K31/185; A61K31/19; A61K31/195; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/4164; A61K31/4178; A61K39/00; A61K39/0005; A61Q; A61Q19/00; A61Q19/08; C; C07; C07D; C07D405/00; C07D405/14; C07K; C07K14/00; C07K14/435; C07K14/705; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5091; G01N33/53; G01N33/531; G01N33/532; G01N33/533; G01N33/573; G01N33/58; G01N33/582; G01N33/68; G01N33/6803; G01N33/6842; G01N33/6893; A61K2039/60; A61K2039/6031; A61K2039/6081; C07K2317/00; C07K2317/70; C07K2317/77; G01N2333/00; G01N2333/90; G01N2333/914; G01N2333/916; G01N2333/922; G01N2800/00; G01N2800/04; G01N2800/042
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
76 words
An isolated receptor protein reactive with advanced glycosylation end products, characterized as follows: (a) it has a molecular mass from 30 to 50 kD; (b) it is reactive with AGE-BSA, AGE-RNAse, AGE-collagen I and AGE-BSA reduced with NaBH 4 and has a binding affinity of 2.0±0.4×10 -6 M -1 (kD=500 nM); (c) it is non-reactive with BSA, collagen I, RNAse or chemically synthesized FFI-BSA; and (d) it is present on mesangial cell membranes prior to purification.
Claim 2
Dependent Claim
76 words
An isolated receptor protein reactive with advanced glycosylation end products, characterized as follows: (a) it has a molecular mass from 30 to 50 kD; (b) it is reactive with AGE-BSA, AGE-RNAse, AGE-collagen I and AGE-BSA reduced with NaBH 4 and has a binding affinity of 2.0±0.4×10 -6 M -1 (kD=500 nM); (c) it is non-reactive with BSA, collagen I, RNAse or chemically synthesized FFI-BSA; and (d) it is present on mesangial cell membranes prior to purification.
Claim 3
Dependent Claim
111 words
A plurality of isolated receptor proteins reactive with advanced glycosylation endproducts, characterized as follows: (a) at least one of said proteins has a molecular mass from 30 to 50 kD; (b) the plurality of proteins is derived from mammalian mesangial cells; (c) the proteins are reactive with AGE-BSA, AGE-RNAse, AGE-collagen I and AGE-BSA reduced with NaBH 4 , having a binding affinity of 2.0±0.4×10 -6 M -1 (kD=500 nM); (d) the proteins are non-reactive with BSA, collagen I, RNAse or chemically synthesized FFI-BSA; and (e) the proteins are present on mesangial cell membranes prior to purification in an amount sufficient to bind about 3.0±0.25×10 5 AGE-modified protein molecules per mesangial cell.
Claim 4
Dependent Claim
111 words
A plurality of isolated receptor proteins reactive with advanced glycosylation endproducts, characterized as follows: (a) at least one of said proteins has a molecular mass from 30 to 50 kD; (b) the plurality of proteins is derived from mammalian mesangial cells; (c) the proteins are reactive with AGE-BSA, AGE-RNAse, AGE-collagen I and AGE-BSA reduced with NaBH 4 , having a binding affinity of 2.0±0.4×10 -6 M -1 (kD=500 nM); (d) the proteins are non-reactive with BSA, collagen I, RNAse or chemically synthesized FFI-BSA; and (e) the proteins are present on mesangial cell membranes prior to purification in an amount sufficient to bind about 3.0±0.25×10 5 AGE-modified protein molecules per mesangial cell.
Claim 5
Dependent Claim
17 words
The protein of claim 1 or the receptor proteins of claim 2 labeled with a detectable label.
Claim 6
Dependent Claim
23 words
An isolated receptor protein reactive with advanced glycosylation end products in accordance with claim 1 having a molecular mass of about 50 kD.
Claim 7
Dependent Claim
23 words
An isolated receptor protein reactive with advanced glycosylation end products in accordance with claim 1 having a molecular mass of about 40 kD.
Claim 8
Dependent Claim
22 words
An isolated receptor protein reactive with advanced glycosylation end products in accordance with claim 1 having a molecular mass of about30-35 kD.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-12 | 1996-10-12 | 1997-04-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-12 | 2000-10-12 | 2001-04-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-12 | 2004-10-12 | 2005-04-13 | $7700.00 | Window Closed / Lapsed |